Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population

Average Settlement in New Jersey for Personal Injury Claims Involving the Neck and Back is $918,967

Work-related Accidents Which Cause Neck and Back Injuries Have a National Average Settlement of $148,750

BROOMFIELD, CO - (NewMediaWire) - September 05, 2024 - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a program to develop a statewide network of providers in New Jersey to utilize Nociscan throughout the personal injury and workers compensation population.

Justin Kubeck, MD, an orthopedic surgeon and founder of Ocean Pain and Spine in Toms River, NJ will initiate a focused effort to improve the objective evaluation of chronic low back pain patients throughout the complex personal injury and workers compensation system that aims to provide the right treatments and financial compensation to patients suffering from injury.

“The personal injury and workers compensation ecosystem involves a discrete number of judges and lawyers who work to adjudicate claims leveraging the expertise of physicians dedicated to understanding this unique segment of the healthcare system. The nature of these claims mandates an objective and definitive diagnosis, knowing that the diagnosis may well be challenged in a legal setting. The use of Nociscan can be a powerful objective measurement tool to provide a strong case for supporting an appropriate treatment pathway,” said Dr. Kubeck. “Over the next several months, I will be working to educate the network of judges and lawyers who determine the appropriateness of recommended treatments on the value Nociscan brings to my patients and the value I think it can bring to improving the workers compensation and personal injury evaluation process.”

Workers compensation and personal injury claims involving the neck and back have significant financial implications for workers, employers, and insurance companies. Although there are many factors that go into the final settlement or jury verdict associated with these cases, whether surgical intervention is required or not is often a clear delineating point for the size of the settlement. Because Nociscan directly measures biomarkers in the lumbar disc correlated to pain and structural integrity, Nociscan is positioned to provide important objective data that providers can use as they formulate and defend their recommended treatment plan.  

Ryan Bond, Chief Strategy Officer of Aclarion, commented, “Once established in New Jersey, we will target other markets throughout the United States to replicate the success of the NJ market.  We believe this population is the perfect fit for the use of advanced biomarker identifications correlated to pain and available exclusively through the Nociscan platform.”

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith

PCG Advisory, Inc.

646.823.8656

ksmith@pcgadvisory.com

Media Contacts:

Jodi Lamberti

SPRIG Consulting

612.812.7477

jodi@sprigconsulting.com